Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glasdegib - Pfizer

Drug Profile

Glasdegib - Pfizer

Alternative Names: DAURISMO; PF 04; PF-04449913; PF-4449913

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Pfizer; Yale University
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia
  • Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I/II Glioblastoma; Graft-versus-host disease
  • Phase I Cancer; Haematological malignancies; Solid tumours

Most Recent Events

  • 04 Dec 2019 Efficacy and adverse events data from the phase Ib/II BRIGHT 1012 trial in Myelodysplastic syndromes and Acute myeloid leukemia presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 19 Nov 2019 Gruppo Italiano Malattie EMatologiche dell'Adulto plans a phase III trial for Acute myeloid leukemia (Combination therapy, First-line therapy) USA (PO) in February 2020 (NCT04168502)
  • 01 Oct 2019 Pfizer plans a phase I/II trial for Graft-versus-host disease (Treatment-experienced) in USA in October 2019 (PO) (NCT04111497)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top